Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gross Profit (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Gross Profit for 3 consecutive years, with $49.9 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 93.18% to $49.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $152.5 million through Dec 2025, up 222.57% year-over-year, with the annual reading at $152.5 million for FY2025, 222.58% up from the prior year.
  • Gross Profit for Q4 2025 was $49.9 million at Phathom Pharmaceuticals, up from $43.3 million in the prior quarter.
  • The five-year high for Gross Profit was $49.9 million in Q4 2025, with the low at $515000.0 in Q4 2023.
  • Average Gross Profit over 3 years is $22.3 million, with a median of $24.8 million recorded in 2025.
  • The sharpest move saw Gross Profit soared 4919.22% in 2024, then surged 93.18% in 2025.
  • Over 3 years, Gross Profit stood at $515000.0 in 2023, then skyrocketed by 4919.22% to $25.8 million in 2024, then surged by 93.18% to $49.9 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $49.9 million, $43.3 million, and $34.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.